Infectious diseases

Jet Health, Inc. Appoints Jake Massacci Vice President of Human Resources

Retrieved on: 
Monday, August 2, 2021
Other Health, Pharmaceutical, Other Policy Issues, Human resources, Infectious diseases, Hospitals, Professional services, Practice Management, Physical therapy, Nursing, Public policy, Government, Managed care, Medical Supplies, Cardiology, FDA, Diabetes, AIDS, Health, Articles, Human resources, Resources, Professional certification, Hospice

Jet Health, Inc. , a leading regional provider of home health and hospice services, announced today the appointment of Jake Massacci to the post of vice president of human resources.

Key Points: 
  • Jet Health, Inc. , a leading regional provider of home health and hospice services, announced today the appointment of Jake Massacci to the post of vice president of human resources.
  • In this capacity, Massacci will be responsible for overseeing all human resources (HR) functions for the Company across several locations nationwide, including recruitment.
  • In addition, Massacci served in several other HR roles, including manager talent acquisition for Texas Health Resources and vice president at Alliance Careers.
  • He is a certified senior professional - human resources, which he earned from the Human Resources Certification Institute.

VBI Vaccines Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 2, 2021
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Medical specialties, Vaccination, Vaccine, Virology, Medicine, COVID-19 vaccines, Clinical trials, Health, Medical research, Variation Biotechnologies

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today reported financial results for the second quarter ending June 30, 2021 and provided a corporate update.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today reported financial results for the second quarter ending June 30, 2021 and provided a corporate update.
  • We look forward to sharing upcoming data and regulatory milestones as we move into the second half of 2021.
  • Revenue: Revenue in the second quarter of 2021 was $0.1 million, compared to $0.2 million for the same period in 2020.
  • Research and Development (R&D): R&D expenses for the second quarter of 2021 were $4.6 million compared to $2.4 million in the second quarter of 2020.

AHF: ‘Providence Journal’ Rejects Ad Skewering CVS’s PBM Abuse

Retrieved on: 
Sunday, August 1, 2021
Retail, AIDS, Health, Courts, Law enforcement, Emergency services, Healthcare reform, Public policy, Government, Pharmaceutical, Convenience store, Managed care, Infectious diseases, State, Local, Public policy, Other Policy Issues, Providence metropolitan area, The Providence Journal, Advertising, Providence, Rhode Island, Geography of Rhode Island, Providence, Mass media in the United States, Articles

AHF intended to run the ad this week in the Providence Journal and had been communicating back and forth with the papers advertising department regarding suggested possible changes or edits to the ad.

Key Points: 
  • AHF intended to run the ad this week in the Providence Journal and had been communicating back and forth with the papers advertising department regarding suggested possible changes or edits to the ad.
  • However, after making some initial changes suggested by the Providence Journal, the papers ad reps then advised AHF the ad could not run.
  • The Providence Journal is the oldest continuously published daily newspaper in the United States.
  • While we are disappointed that the Providence Journal will not run our Corporate Vampires Suck advocacy ad, we are not entirely surprised.

AHF: The G20 Manifesto Calls on Leaders to Vaccinate Our World!

Retrieved on: 
Friday, July 30, 2021
Public policy, Government, Pharmaceutical, White House, Federal Government, AIDS, Public policy, Health, Healthcare reform, Infectious diseases, G20, Articles, World, Organizations

The Manifesto outlines seven actions G20 leaders must take before the meeting to Vaccinate Our World and put the world on a path to defeating the pandemic.

Key Points: 
  • The Manifesto outlines seven actions G20 leaders must take before the meeting to Vaccinate Our World and put the world on a path to defeating the pandemic.
  • Were issuing this Manifesto and starting a countdown to the G20 summit in Rome because there is currently no sense of urgency to vaccinate our world.
  • G20 leaders must be the catalyst for ensuring global vaccine equity, and their annual meeting is the ideal venue to make it happen.
  • The G20 Manifesto lists specific actions that can help get lifesaving vaccines to everyone who needs them.

ParaPRO Announces Availability of Natroba™ (spinosad) Topical Suspension, 0.9% for the Treatment of Scabies

Retrieved on: 
Monday, August 2, 2021
Infectious diseases, Medical specialties, Medicine, Scabies, Topical medication

"We are pleased to offer healthcare providers and their patients the first pharmacological advancement in scabies treatment in decades.

Key Points: 
  • "We are pleased to offer healthcare providers and their patients the first pharmacological advancement in scabies treatment in decades.
  • Natroba is a targeted topical therapy that was shown to be highly effective and well-tolerated in the treatment of scabies following one application of the study drug."
  • Natroba Topical Suspension is a scabicide indicated for the topical treatment of scabies infestations in adult and pediatric patients four (4) years of age and older.
  • If any member of a household presents with scabies, all household members should be treated with Natroba Topical Suspension.

Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

Retrieved on: 
Monday, August 2, 2021
Health sciences, Medicine, Clinical medicine, Zoonoses, Infectious diseases, Nose, Dosage forms, Pandemics, Virus, COVID-19, Nasal spray

It has been tested in healthy volunteers and patients as part of UK and Canada clinical trials.

Key Points: 
  • It has been tested in healthy volunteers and patients as part of UK and Canada clinical trials.
  • Available in the form of a simple nasal spray, it is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs.
  • SaNOtize developed and patented a Nitric Oxide Releasing Solution platform technology (NORS) to treat and prevent microbial infections in 2017.
  • Available at https://www.clinicaltrialsarena.com/news/sanotize-nasal-spray-reduces-co...
    2 SaNOtize's "revolutionary" Covid-19 nasal spray bolstered by Phase II trial data.

GEHA Extends Vaccination Incentive Program to Encourage U.S. COVID-19 Vaccinations

Retrieved on: 
Friday, July 30, 2021
Insurance, Pharmaceutical, Human resources, Managed care, Health, Infectious diseases, Hospitals, Professional services, GEHA, Vaccination, COVID-19 vaccine, Articles

announced it will extend the previously launched COVID-19 Vaccination Incentive Program for GEHA medical plan members to September 6, 2021.

Key Points: 
  • announced it will extend the previously launched COVID-19 Vaccination Incentive Program for GEHA medical plan members to September 6, 2021.
  • GEHA members have the opportunity to secure both the GEHA incentive and their state and local governments depending on where they reside.
  • Extending the Vaccination Incentive Program is paramount to our commitment to our members and their families, said Interim President and CEO of GEHA Rich Bierman.
  • Eligible members are able to sign up for GEHAs COVID-19 Vaccination Incentive Program and submit proof of vaccination.

DGAP-News: MediClin AG: The demand for non-corona-induced medical and therapeutic measures has been increasing since mid-2021

Retrieved on: 
Friday, July 30, 2021
Contemporary history, Occupational safety and health, COVID-19 pandemic, Pandemics, Public Health Emergency of International Concern, Articles, Infectious diseases

At operating level, without benefits under the protective shield, Group sales increased by EUR 15.9 mill.

Key Points: 
  • At operating level, without benefits under the protective shield, Group sales increased by EUR 15.9 mill.
  • Compared to 2019 before the coronavirus pandemic, sales without benefits under the protective shield are still EUR 25.3 mill.
  • The interdisciplinary expertise that MEDICLIN has in the treatment of post-COVID and long-COVID patients is reflected in a significantly increasing demand.
  • ber die MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)
    Zu MEDICLIN gehren 35 Kliniken, sieben Pflegeeinrichtungen und zehn Medizinische Versorgungszentren.

SCYNEXIS Announces Two Oral Presentations on Pooled Data from the BREXAFEMME (Ibrexafungerp tablets) Phase 3 VANISH Program Demonstrating Consistent Efficacy in the Treatment for Vaginal Yeast Infections at the IDSOG 2021 Virtual Annual Meeting

Retrieved on: 
Thursday, July 29, 2021
Antifungals, Infectious diseases, Branches of biology, Pathogenic microbes, Yeasts, Medical specialties, Echinocandins, Candida auris, Cándida, 1,3-Beta-glucan synthase, Caspofungin

Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.

Key Points: 
  • Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.
  • This agent combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations.
  • Ibrexafungerp is in late-stage development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients.
  • The New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021.

Excision BioTherapeutics Appoints Industry Veteran Lisa Danzig, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, July 29, 2021
Infectious diseases, Academic journals, Publications, Periodicals, Medical research, Biotechnology

SAN FRANCISCO, July 29, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc, the developer of CRISPR-based therapies intended to cure viral infectious diseases, today announced the appointment of Lisa Danzig, M.D., as Chief Medical Officer.

Key Points: 
  • SAN FRANCISCO, July 29, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc, the developer of CRISPR-based therapies intended to cure viral infectious diseases, today announced the appointment of Lisa Danzig, M.D., as Chief Medical Officer.
  • Most recently, she has worked with Pandefense Advisory helping various institutions, non-profits, companies, and governments around the world on COVID-19 responses and protocols.
  • Dr. Danzig previously served as EVP and Chief Medical Officer at infectious disease and travel vaccine developer, PaxVax.
  • Excision BioTherapeutics, Inc., is a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases.